Timing and durability of response to erenumab in patients with chronic migraine

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

(2021) Messoud Ashina et al.   EUROPEAN JOURNAL OF NEUROLOGY

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

(2019) David W Dodick   CEPHALALGIA

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in chronic migraine with medication overuse

(2019) Stewart J. Tepper et al.   NEUROLOGY

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

(2018) Cristina Tassorelli et al.   CEPHALALGIA

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

(2018)   HEADACHE

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies

(2018) Russell Nichols et al.   HEADACHE

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

(2018) Todd Schwedt et al.   JOURNAL OF HEADACHE AND PAIN

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

(2017) Daniel Serrano et al.   JOURNAL OF HEADACHE AND PAIN

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Erenumab (AMG 334) in episodic migraine

(2017) Messoud Ashina et al.   NEUROLOGY

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

(2017) Thuy Vu et al.   PHARMACEUTICAL RESEARCH

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

(2015) Lars Edvinsson   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Post Hoc Analyses

(2015) Titte R. Srinivas et al.   TRANSPLANTATION

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains

(2014) Rami Burstein et al.   CEPHALALGIA

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT

(2014) Stephen D Silberstein et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY